Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified

Teva Pharmaceutical Industries

(

TEVA

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Teva Pharmaceutical Industries as such a stock due to the following factors:

  • TEVA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $438.8 million.
  • TEVA has traded 1.3 million shares today.
  • TEVA is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in TEVA with the Ticky from Trade-Ideas. See the FREE profile for TEVA NOW at Trade-Ideas

More details on TEVA:

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The stock currently has a dividend yield of 1.8%. TEVA has a PE ratio of 43. Currently there are 9 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 7 rate it a hold.

The average volume for Teva Pharmaceutical Industries has been 3.8 million shares per day over the past 30 days. Teva has a market cap of $53.7 billion and is part of the health care sector and drugs industry. Shares are up 8.7% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Teva Pharmaceutical Industries as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:

  • Net operating cash flow has significantly increased by 50.77% to $1,354.00 million when compared to the same quarter last year. In addition, TEVA PHARMACEUTICALS has also vastly surpassed the industry average cash flow growth rate of -59.86%.
  • The gross profit margin for TEVA PHARMACEUTICALS is rather high; currently it is at 63.49%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, TEVA's net profit margin of 8.95% significantly trails the industry average.
  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period, despite the company's weak earnings results. Looking ahead, unless broad bear market conditions prevail, we still see more upside potential for this stock, despite the fact that it has already risen over the past year.
  • TEVA PHARMACEUTICALS's earnings per share declined by 40.2% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, TEVA PHARMACEUTICALS increased its bottom line by earning $3.56 versus $1.50 in the prior year. This year, the market expects an improvement in earnings ($5.23 versus $3.56).

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.